Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and optimal dosage of caspofungin in critically ill patients
2012-003617-34Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2012
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of caspofungin in invasive candidiasis, sponsored by University Medical Center Groningen. Primary endpoint: Adequate exposure to caspofungin (AUC ≥ 98 mg·h/L). Started Nov 2012; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive candidiasis
Beyond the preview
Go deeper on 2012-003617-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003617-34.